Are you over 18 and want to see adult content?
More Annotations
A complete backup of dreammaker.co.uk
Are you over 18 and want to see adult content?
A complete backup of welcome2japan.hk
Are you over 18 and want to see adult content?
A complete backup of ondas-electromagneticas-uv.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of britmodeller.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://worldinsurancereport.com
Are you over 18 and want to see adult content?
A complete backup of https://freestateproject.org
Are you over 18 and want to see adult content?
A complete backup of https://getdata.com
Are you over 18 and want to see adult content?
A complete backup of https://stadissa.fi
Are you over 18 and want to see adult content?
A complete backup of https://exif.org
Are you over 18 and want to see adult content?
A complete backup of https://marekmach.cz
Are you over 18 and want to see adult content?
A complete backup of https://in-communication.ru
Are you over 18 and want to see adult content?
A complete backup of https://nacva.com
Are you over 18 and want to see adult content?
A complete backup of https://asmodee.it
Are you over 18 and want to see adult content?
A complete backup of https://gritdaily.com
Are you over 18 and want to see adult content?
A complete backup of https://readcereal.com
Are you over 18 and want to see adult content?
A complete backup of https://billmaher.com
Are you over 18 and want to see adult content?
Text
May
20210212 LOCAL MANUFACTURING OF COVID 19 VACCINE REACHES Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling. The release follows the completion of the final stages of manufacture – known as fill and finish – and extensive quality checks at Seqirus’ vaccine facilities in Parkville,Melbourne.
20210512 CSL WELCOMES GOVERNMENT COMMITMENT TO DOMESTIC Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA vaccine manufacturing capability. While mRNA vaccine technology has been explored by researchers for many years, the COVID-19 pandemic has accelerated this technology from what was a promising science to a viable technology platform that can be produced at industrial scale. DIVIDENDS | CSL LIMITED CSL is a global biotech leader. We do business in over 60 countries, with major facilities around the world. Learn more.JOY LINTON - CSL
Joy Linton was named Chief Financial Officer in October 2020 and leads the Global Finance organization, including both the CSL Behring and Seqirus businesses, and its accompanying strategy. In this role, Joy is responsible for managing the financial aspects of CSL’s strategy and serves as the company’s chief financial steward. DIVERSITY AND INCLUSION POLICY Diversity and Inclusion Policy 1 Purpose CSL’s employee brand — Promising Futures — speaks to our commitment to building a workplace where employees can fulfill their career aspirations, realize their potential and be inspired by being part of a ALAN WILLS | CSL BEHRING Alan Wills is responsible for strategy, business development and portfolio management activities at CSL Behring. Alan joined CSL Behring as SVP Strategy and Business Development in 2015. Prior to joining CSL, he was EVP, Corporate Development at Auxilium Pharmaceuticals. He was also head of corporate strategy for Bristol-Myers Squibb and Pfizer SECURITIES DEALING POLICY Date Effective 1 May 2017 CSL Securities Dealing Policy CSL.com CSLBehring.com 2 Securities Dealing Policy Term/Abbreviation Description CSL CSL Limited (ABN 99 051 588 348). CSL Group CSL and its controlled entities. CSL Person and CSL NAMED ONE OF THE TOP COMPANIES IN THE WORLD FOR MELBOURNE, Australia. – September 18, 2018 – Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and Inclusion Index. This achievement reflects CSL’s promise to build a workplace culture where employees have a promising future and can fulfill their career aspirations, realize their potential and be part of a purpose CSL DELIVERS A FULL YEAR NET PROFIT OF OVER $2.1 BILLION1 For immediate release 19 August 2020 CSL Delivers a Full Year Net Profit of over $2.1 Billion1 CSL delivered another strong year, with reported net profit after tax of $2,103 million, up 20210501 UPDATE ON CSL COVID-19 VACCINE MANUFACTURING … Update on CSL COVID-19 Vaccine Manufacturing Numbers. 01 May 2021. news. Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number of weeks and are due to be released into the community from mid-lateMay
20210212 LOCAL MANUFACTURING OF COVID 19 VACCINE REACHES Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling. The release follows the completion of the final stages of manufacture – known as fill and finish – and extensive quality checks at Seqirus’ vaccine facilities in Parkville,Melbourne.
20210512 CSL WELCOMES GOVERNMENT COMMITMENT TO DOMESTIC Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA vaccine manufacturing capability. While mRNA vaccine technology has been explored by researchers for many years, the COVID-19 pandemic has accelerated this technology from what was a promising science to a viable technology platform that can be produced at industrial scale. DIVIDENDS | CSL LIMITED CSL is a global biotech leader. We do business in over 60 countries, with major facilities around the world. Learn more.JOY LINTON - CSL
Joy Linton was named Chief Financial Officer in October 2020 and leads the Global Finance organization, including both the CSL Behring and Seqirus businesses, and its accompanying strategy. In this role, Joy is responsible for managing the financial aspects of CSL’s strategy and serves as the company’s chief financial steward. DIVERSITY AND INCLUSION POLICY Diversity and Inclusion Policy 1 Purpose CSL’s employee brand — Promising Futures — speaks to our commitment to building a workplace where employees can fulfill their career aspirations, realize their potential and be inspired by being part of a ALAN WILLS | CSL BEHRING Alan Wills is responsible for strategy, business development and portfolio management activities at CSL Behring. Alan joined CSL Behring as SVP Strategy and Business Development in 2015. Prior to joining CSL, he was EVP, Corporate Development at Auxilium Pharmaceuticals. He was also head of corporate strategy for Bristol-Myers Squibb and Pfizer SECURITIES DEALING POLICY Date Effective 1 May 2017 CSL Securities Dealing Policy CSL.com CSLBehring.com 2 Securities Dealing Policy Term/Abbreviation Description CSL CSL Limited (ABN 99 051 588 348). CSL Group CSL and its controlled entities. CSL Person and CSL NAMED ONE OF THE TOP COMPANIES IN THE WORLD FOR MELBOURNE, Australia. – September 18, 2018 – Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and Inclusion Index. This achievement reflects CSL’s promise to build a workplace culture where employees have a promising future and can fulfill their career aspirations, realize their potential and be part of a purpose CSL DELIVERS A FULL YEAR NET PROFIT OF OVER $2.1 BILLION1 For immediate release 19 August 2020 CSL Delivers a Full Year Net Profit of over $2.1 Billion1 CSL delivered another strong year, with reported net profit after tax of $2,103 million, up CSL LIMITED IS A GLOBAL BIOTECH LEADER. CSL Limited is a global biotech leader. 2020 CSL Research Acceleration Initiative Awardees Announced. Learn More. CSL Dispatches First Australian Made Doses of the AstraZeneca COVID 19 Vaccine. Learn More. Our 2021 Half Year Financial Results information and webcast recording is now available. Learn More. Popular search terms: 20210512 CSL WELCOMES GOVERNMENT COMMITMENT TO DOMESTIC Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA vaccine manufacturing capability. While mRNA vaccine technology has been explored by researchers for many years, the COVID-19 pandemic has accelerated this technology from what was a promising science to a viable technology platform that can be produced at industrial scale.FINANCIAL CALENDAR
Financial Calendar - Events. 2021. 18 February. Half year profit and interim dividend announcement. 4 March. Shares traded ex-dividend. 5 March. Record date for interim dividend. 1 April. 20210506 CSL BEHRING ANNOUNCES GLOBAL COMMERCIALIZATION CSL Behring Announces Global Commercialization and License Agreement with uniQure. Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding. uniQure will complete the Phase 3 HOPE-B trial and scale up HALF YEAR RESULTS 2020 Half Year Results 2020. CSL Limited announced Half Year Results for the period ending 31st December 2019 on Wednesday, 12th February 2020 (AEDT) Full details including a link to the webcast presentation, can be viewed via the link below. Learn More.BRUCE BROOK
Independent Non-executive Director. Mr Bruce Brook has been a Director of CSL Limited since August 2011. Skills and experience. Mr Brook has an extensive breadth of executive experience in diverse industries, including mining, finance, manufacturing and chemicals.CSL LIMITED
CSL Limited. Macquarie Conference. 5 May, 2021. Paul McKenzie, PhD Chief Operating Officer SECURITIES DEALING POLICY Date Effective 1 May 2017 CSL Securities Dealing Policy CSL.com CSLBehring.com 2 Securities Dealing Policy Term/Abbreviation Description CSL CSL Limited (ABN 99 051 588 348). CSL Group CSL and its controlled entities. CSL Person andCSL SPEAK UP POLICY
CSL Speak Up Policy 1 What is the purpose of this policy? CSL Limited and its subsidiaries (CSL) are committed to conducting business honestly, with integrity, and . in accordance with its values and standards of expected behaviour as outlined in CSL’s Code ofResponsible
PLASMA THERAPIES AND VACCINES Safety & Manufacture Of Plasma Therapies. Every medicine possesses some level of safety risk. For plasma - derived therapies, the most important safety issue is the potential for contamination with pathogens originating from the plasma used to manufacture these therapies. Although the theoretical risk of pathogen transmission cannever be zero
Skip to main content * Global Selector __*
* Partnering
* Contact
*
Our Company
Our Company__
Our Story__
Corporate Responsibility__In The Community__
In The Community__
Patient Support Groups__ Access to Medicines__Disaster Relief__
Promoting Excellence in Science__ Next Generation of Researchers__ Board and Management__ Board and Management__ Global Leadership Group__ Corporate Governance__ Corporate Governance__ Code of Responsible Business Practice__Core Policies__
The Commonwealth Serum Laboratories was established in Australia in1916.
Learn More
At CSL, Corporate Responsibility is about conducting our businessethically.
Learn More
*
Expertise
Expertise__
Rare and Serious Diseases__ Influenza Vaccines and Antivenoms__ We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.Learn More
Seqirus opened in 2015, born from the merging of CSL's bioCSL division and the Novartis influenza vaccine business.Learn More
*
R&D
R&D__
R&D Capabilities__
Product Pipeline__
Clinical Studies at CSL__ Clinical Studies at CSL__ Current Clinical Trials__ Research Practices__ What is a Clinical Trial__ What is a Clinical Trial__ Rights and Responsibilities__ Enrolling in a Clinical Trial__FAQs__
Questions to Ask the Study Team__ Innovation has been in the DNA of CSL since our beginning in 1916Learn More
Our product portfolio focuses on innovation in new productsLearn More
*
Investors
Investors__
CSL Share Price__
Financial Results and Information__ Financial Results and Information__Five Year Summary__
Debt Information__
Annual Reports__
Financial Calendar__ASX Announcements__
Presentations__
Dividends__
Shareholder Information__ Shareholder Information__ Shareholder Inquiries__Contact Us__
Our interim dividend for 2019 increased to US$0.85 per share, up 8%.Learn More
Our exceptionally strong performance is a result of the focused execution of our strategy.Learn More
*
Careers
Careers__
See Yourself at CSL__ Diversity & Inclusion__ How We Care for You at CSL__ Discover Our People__ Help us deliver on our promise to save lives and protect the health ofpeople.
Learn More
Make your well-being a priority. It's important and so are you.Learn More
*
News
News__
Newsroom__
View our ASX announcementsASX announcements
Visit this page to see all of our current news releasesNewsroom
* __
* __
* __
CSL
__ __Back
*
Our Company __
*
Our Company __
*
Our Story __
*
Corporate Responsibility __*
In The Community __
*
In The Community __
*
Patient Support Groups __*
Access to Medicines __*
Disaster Relief __
*
Promoting Excellence in Science __*
Next Generation of Researchers __*
Board and Management __*
Board and Management __*
Global Leadership Group __*
Corporate Governance __*
Corporate Governance __*
Code of Responsible Business Practice __*
Core Policies __
*
Expertise __
*
Expertise __
*
Rare and Serious Diseases __*
Influenza Vaccines and Antivenoms __*
Research & Development __*
Research & Development __*
R&D Capabilities __
*
Product Pipeline __
*
Clinical Studies at CSL __*
Clinical Studies at CSL __*
Current Clinical Trials __*
Research Practices __*
What is a Clinical Trial __*
What is a Clinical Trial __*
Rights and Responsibilities __*
Enrolling in a Clinical Trial __*
FAQs __
*
Questions to Ask the Study Team __*
Investors __
*
Investors __
*
CSL Share Price __
*
Financial Results and Information __*
Financial Results and Information __*
Five Year Summary __*
Debt Information __
*
Annual Reports __
*
Financial Calendar __*
ASX Announcements __*
Presentations __
*
Dividends __
*
Shareholder Information __*
Shareholder Information __*
Shareholder Inquiries __*
Contact Investor Relations __*
Careers __
*
Careers __
*
See Yourself at CSL __*
Diversity & Inclusion __*
How We Care for You at CSL __*
Discover Our People __*
News __
*
News __
*
Newsroom __
OUR 2019 FULL YEAR RESULTS WEBCAST WILL BE LIVE FROM 11AM, 14TH AUGUST2019 (AEST)
Register For Webcast VIEW OUR 2017/18 ANNUAL REPORTLearn More
THE FELLOWS ARE A GROUP OF EXCEPTIONALLY BRIGHT YOUNG AUSTRALIANS.Learn More
__ __
OUR 2019 FULL YEAR RESULTS WEBCAST WILL BE LIVE FROM 11AM, 14TH AUGUST2019 (AEST)
Register For Webcast VIEW OUR 2017/18 ANNUAL REPORTLearn More
THE FELLOWS ARE A GROUP OF EXCEPTIONALLY BRIGHT YOUNG AUSTRALIANS.Learn More
Popular search terms:* full year results
* share price
* 2019 results
* annual report
* news
* All
* Innovation
* Company
__ __
CSL TO MOVE GLOBAL HEADQUARTERS Major landmark development will significantly increase CSL’s presence in the Parkvill…Read More
07 Aug 2019 Company
CSL RENEWS PARTNERSHIP WITH NYSF MELBOURNE, Australia - CSL today announced its continued partnershipwith the Nationa…
Read More 15
Mar 2019 Company
CSL AT J.P. MORGAN'S 2019 HEALTHCARE CONFERENCE CSL Limited today announced that it will present at the 2019 J.P. Morgan Annual Healt…Read More
07 Jan 2019 Company
NANCY MILLIS BUILDING OPENS AT BIO21 INSTITUTE The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, …Read More
14 Dec 2018 Company
DEVELOPMENTS IN CELL-BASED VACCINE TECHNOLOGY CSL spotlights developments in cell-based vaccine technology at Australian Research a…Read More
05 Dec 2018 Innovation 2019 CENTENARY FELLOWSHIP WINNERS ANNOUNCED Two Australian scientists have each been awarded an AUD$1.25 million,five-year, CSL …
Read More
11 Oct 2018 Company
See all news
WE ARE PASSIONATE ABOUT PEOPLEMIKE DEEM
SENIOR VICE PRESIDENT AND GENERAL MANAGER, CSL PLASMA When Mike Deem joined CSL nearly 30 years ago, he was a college student in search of tuition reimbursement. That college job turned into an exciting career. He's now SVP and General Manager of CSL Plasma and credits his success to the mentors and development opportunities provided by the company. FOCUSED ON THE FUTURE We are committed in the long-term to support world-class medical research and development.Learn More
OUR PROMISE HAS NEVER BEEN STRONGER. We understand the unique challenges faced by people with life threatening medical conditions because of our long experience, deep knowledge and dedicated focus on serious diseases. Review our 2017/18 Annual ReportOUR COMPANY
See how we are driven by our promise.Learn More
CAREERS
Join us and make history with the brightest, most passionate people from every discipline.Learn More
NEWS
Find out what's happening now at CSL.Learn More
GET OUR LATEST NEWS IN YOUR INBOX*
Emailmail@example.com First NameFirst nameLast NameLast name
CountryCountry
I would like to receiveKey ASX releases
Media releases
Captcha
THANKS!
Thank you for subscribing__
to the CSL newsletter* Contact
*
*
*
CSL Limited, All Rights Reserved © 2019* Glossary
* Sitemap
* Privacy Policy
* Terms of Use
* Employees
*
*
*
* Contact
* Glossary
* Sitemap
* Privacy Policy
* Terms of Use
* Employees
CSL Limited, All Rights Reserved © 2019 Popular search terms:* full year results
* share price
* 2019 results
* annual report
* news
__
Play
PausePlay
Seek% buffered00:00UnmuteMuteDisable captionsEnable captionsExit fullscreenEnter fullscreen __CORPORATE
* CSL Behring (Global)SEQIRUS
* Global
Americas
* United States
Asia Pacific
* Australia
* New Zealand
Europe
* Germany
* Italy
CSL BEHRING WORLDWIDEAmericas
* Argentina
* Brazil
* Canada
* Chile
* CSL Behring Global* CSL Plasma (US)
* Mexico
Asia Pacific
* Australia
* China
* Japan
Europe
* Austria
* Belgium and Luxembourg * CSL Plasma Services (Germany)* Czech Republic
* Denmark
* Finland
* France
* Germany
* Greece
* Hungary
* Italy
* Netherlands
* Norway
* Poland
* Russia
* Spain
* Sweden
* Switzerland
* Turkey
* United Kingdom
__
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0